Adverse Effects

Brain Cancer

HER2-Positive Breast Cancer

Triple-Negative Breast Cancer

Breast Cancer

Colorectal Cancer

Esophageal Cancer

Gastric Cancer

Liver Cancer

Pancreatic Cancer

Gastrointestinal Cancer

Bladder Cancer

Kidney Cancer

Prostate Cancer

Genitourinary Cancers

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

Gynecologic Cancers

Head & Neck Cancer

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Hematologic Oncology

Vaccines

Infection

Leukemia

Non-Small Cell Lung Cancer (NSCLC)

Small Cell Lung Cancer (SCLC)

Lung Cancer

Lymphoma

Neuroendocrine Tumors

Oncology

Pediatric Cancers

Radiation Oncology

Sarcoma

Screening

Skin Cancer & Melanoma

Surgery

Thyroid Cancer

News

Global Bulletin

All News

FDA Approval Alert

Women in Oncology

Media

Around the Practice

Between the Lines

Face Off

From All Angles

Meeting of the Minds

OncView

Podcasts

Training Academy

Treatment Algorithms with the Oncology Brothers

Videos

Conferences

Publications

All Journals

Editorial Board

For Authors

Year in Review

Events

Frontline Forum

Satellite Sessions

CME/CE

Resources

Awareness Month

Nurse Practitioners/Physician's Assistants

Partners

Career Center

Subscribe

CancerNetwork is home to the journal Oncology & provides insights on the screening, early detection, diagnosis, treatment and prevention of cancers.

About

Advertise

CureToday.com

OncLive.com

OncNursingNews.com

TargetedOnc.com

Editorial

Contact

Terms and Conditions

Privacy

Do Not Sell My Personal Information

CancerNetwork - Oncology News and Clinical Expertise

Facebook

LinkedIn

Youtube

Spotlight

Clinical

Genitourinary Cancer

Gynecologic Cancer

Hematology

Skin Cancer

1rem

View

Navigating Adverse Events and Toxicities in NSCLC Therapy: Challenges and Strategies

Video Series

Closing Thoughts on the Future of NSCLC

Alexander Spira, MD, PhD, FACP; Sandip Patel, MD; Estelamari Rodriguez, MD, MPH, and Christine Bestvina, MD, analyze real-world non-small cell lung cancer cases, sharing their treatment strategies and insights gained from their clinical experiences.

Sandip Patel, MD, presents a case study of a 62-year-old female patient with a PD-L1 expression of 60%, an EGFR exon 20 insertion mutation, and liver lesions, followed by a panel discussion on diagnostic strategies to optimize patient care.

Patient Case 1: A 62-Year-Old Female with NSCLC

Christine Bestvina, MD, presents her treatment strategy for a 62-year-old female with NSCLC, bone and liver metastases, and an EGFR exon 20 insertion; the panel then assesses clinical data, including the MARIPOSA trial, to guide their treatment decisions.

Systemic Treatment Options for Non-Small Cell Lung Cancer 

The panelists explore the importance of communicating with patients, nurses, and caregivers about potential adverse reactions and injection site reactions, while emphasizing the need to offer ongoing reassurance and support throughout the treatment journey.

Counseling Patients and Caregivers on NSCLC Treatment Toxicities

Alexander Spira, MD, PhD, FACP, presents a case of a 45-year-old male with stage IV NSCLC, bone and liver metastases, and an EGFR exon 20 insertion; the panel then discusses their approach to treating brain metastases using stereotactic radiosurgery radiation therapy.

Patient Case 2: A 45-Year-Old Man with NSCLC Stage IV with Bone and Liver Metastases

Christine Bestvina, MD, presents a case of a 34-year-old non-smoker diagnosed with Stage IIIA NSCLC after presenting with chest wall pain; the panel then explores their approaches to managing toxicities, including rashes and sores, by employing dose reductions and steroids to control adverse reactions.

Patient Case 3: A 34-Year-Old Non-Smoker with Stage IIIA NSCLC

Estelamari Rodriguez, MD, MPH, presents a case of a 50-year-old African American woman, non-smoker, with pleural metastases; the panel discusses interstitial lung disease management, the use of antibody-drug conjugates, disease timing, and strategies for providing symptomatic relief, specifically considering drug holds if steroids only offer partial relief.

Patient Case 4: 50-Year-Old Woman Non-Smoker with Pleural Metastases

Medical experts explore the advantages and disadvantages of next-generation sequencing testing, highlighting the disparities in the quantity of tissue samples being sent for analysis, which can lead to inconclusive results when insufficient sample sizes are provided. 

Molecular Testing: Key Takeaways on Next Generation Sequencing in NSCLC 

In their closing remarks, the panel reflects on the presented patient cases and shares insights on the future of non-small cell lung cancer (NSCLC) treatment. 

Closing Thoughts on the Future of NSCLC 

During a Training Academy focused on first-line treatment use in non–small cell lung cancer, panelists discussed a patient case and how they would treat that patient in the setting.

Amivantamab Is Preferred First-Line Pick in EGFR Exon 20 NSCLC

Closing Thoughts on the Future of NSCLC

EP: 1.Patient Case 1: A 62-Year-Old Female with NSCLC

EP: 2.Systemic Treatment Options for Non-Small Cell Lung Cancer

EP: 3.Counseling Patients and Caregivers on NSCLC Treatment Toxicities

EP: 4.Patient Case 2: A 45-Year-Old Man with NSCLC Stage IV with Bone and Liver Metastases

EP: 5.Patient Case 3: A 34-Year-Old Non-Smoker with Stage IIIA NSCLC

EP: 6.Patient Case 4: 50-Year-Old Woman Non-Smoker with Pleural Metastases

EP: 7.Molecular Testing: Key Takeaways on Next Generation Sequencing in NSCLC

EP: 8.Closing Thoughts on the Future of NSCLC

EP: 9.Amivantamab Is Preferred First-Line Pick in EGFR Exon 20 NSCLC